{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:42:59Z","timestamp":1772142179400,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005688","name":"Gottfried und Julia Bangerter-Rhyner-Stiftung","doi-asserted-by":"publisher","award":["8472"],"award-info":[{"award-number":["8472"]}],"id":[{"id":"10.13039\/501100005688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Scand J Trauma Resusc Emerg Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13049-019-0625-3","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T15:05:25Z","timestamp":1556031925000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4067-7174","authenticated-orcid":false,"given":"Martin","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Eastline","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristomenis K.","family":"Exadaktylos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1182\/blood-2013-09-529784","volume":"123","author":"DM Siegal","year":"2014","unstructured":"Siegal DM, Garcia DA, Crowther MA. How I treat target-specific oral anticoagulant-associated bleeding. Blood. 2014;123:1152\u20138.","journal-title":"Blood."},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack","year":"2017","unstructured":"Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal \u2014 full cohort analysis. N Engl J Med. 2017;377:431\u201341.","journal-title":"N Engl J Med"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/bloodadvances.2017007112","volume":"1","author":"D Siegal","year":"2017","unstructured":"Siegal D, Lu G, Leeds JM, Karbarz M, Castillo J, Mathur V, et al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv. 2017;1:1827\u201338.","journal-title":"Blood Adv"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131\u201341.","journal-title":"N Engl J Med"},{"key":"625_CR5","volume":"148","author":"TC Sauter","year":"2018","unstructured":"Sauter TC, Eberle B, Wuillemin WA, Thiele T, Angelillo-Scherrer A, Exadaktylos AK, et al. How I manage patients with anticoagulation-associated bleeding or urgent surgery. Swiss Med Wkly. 2018;148:w14598.","journal-title":"Swiss Med Wkly"},{"key":"625_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","volume":"24","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of Antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical care society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6\u201346.","journal-title":"Neurocrit Care"},{"key":"625_CR7","doi-asserted-by":"crossref","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, et al. Updated European heart rhythm association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2016:ehw058.","DOI":"10.1093\/eurheartj\/ehw058"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","volume":"168","author":"A-C Martin","year":"2013","unstructured":"Martin A-C, Le Bonniec B, Fischer A-M, Marchand-Leroux C, Gaussem P, Samama C-M, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168:4228\u201333.","journal-title":"Int J Cardiol"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.thromres.2018.01.008","volume":"163","author":"JR Shaw","year":"2018","unstructured":"Shaw JR, Castellucci L, Siegal D, Stiell I, Syed S, Lampron J, et al. Management of direct oral anticoagulant associated bleeding: results of a multinational survey. Thromb Res. 2018;163:19\u201321.","journal-title":"Thromb Res"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMe1800041","volume":"378","author":"J Hirsh","year":"2018","unstructured":"Hirsh J, Ginsberg JS. Edoxaban for the treatment of venous thromboembolism in patients with Cancer. N Engl J Med. 2018;378:673\u20134.","journal-title":"N Engl J Med"},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of Cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615\u201324.","journal-title":"N Engl J Med"},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jocn.2018.01.004","volume":"50","author":"K Bekelis","year":"2018","unstructured":"Bekelis K, Chang C-H, Malenka D, Morden NE. Direct oral anticoagulant and antiplatelet combination therapy: hemorrhagic events in coronary artery stent recipients. J Clin Neurosci. 2018;50:24\u20139.","journal-title":"J Clin Neurosci"},{"key":"625_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699\u2013708.","journal-title":"N Engl J Med"},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781\u20139.","journal-title":"Eur Heart J"},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"J Mega","year":"2009","unstructured":"Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29\u201338.","journal-title":"Lancet"},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143:241.","journal-title":"Ann Intern Med"},{"key":"625_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH13-02-0150","volume":"110","author":"J Desai","year":"2013","unstructured":"Desai J, Kolb J, Weitz J, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants \u2013 defining the issues and the management strategies. Thromb Haemost. 2013;110:205\u201312.","journal-title":"Thromb Haemost"},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.3748\/wjg.v23.i11.1954","volume":"23","author":"K-S Cheung","year":"2017","unstructured":"Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017;23:1954.","journal-title":"World J Gastroenterol"},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","volume":"391","author":"N Sprigg","year":"2018","unstructured":"Sprigg N, Flaherty K, Appleton JP, Salman RA-S, Bereczki D, Beridze M, et al. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018;391:2107\u201315.","journal-title":"Lancet"},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.ejim.2015.12.009","volume":"29","author":"TC Sauter","year":"2016","unstructured":"Sauter TC, Amylidi A-L, Ricklin ME, Lehmann B, Exadaktylos AK. Direct new oral anticoagulants in the emergency department: experience in everyday clinical practice at a Swiss university hospital. Eur J Intern Med. 2016;29:e13\u20135.","journal-title":"Eur J Intern Med"},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1393057","volume":"2016","author":"TC Sauter","year":"2016","unstructured":"Sauter TC, Blum S, Nagler M, Schlittler FL, Ricklin ME, Exadaktylos AK. Reversal of dabigatran using Idarucizumab in a septic patient with impaired kidney function in real-life practice. Case Rep Emerg Med. 2016;2016:1\u20133.","journal-title":"Case Rep Emerg Med"},{"key":"625_CR22","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1001\/jama.2017.13883","volume":"318","author":"S-H Chang","year":"2017","unstructured":"Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, et al. Association between use of non-vitamin K Oral anticoagulants with and without concurrent medications and risk of major bleeding in Nonvalvular atrial fibrillation. JAMA. 2017;318:1250\u20139.","journal-title":"JAMA."}],"container-title":["Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-019-0625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13049-019-0625-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-019-0625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T23:18:45Z","timestamp":1587511125000},"score":1,"resource":{"primary":{"URL":"https:\/\/sjtrem.biomedcentral.com\/articles\/10.1186\/s13049-019-0625-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1186\/s13049-019-0625-3","relation":{},"ISSN":["1757-7241"],"issn-type":[{"value":"1757-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]},"assertion":[{"value":"11 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for informed consent was waived by the ethics committee of Canton Bern, Switzerland, as the patient data were anonymous and part of routine patient care. The study is registered with the responsible ethics committee under the number 073\/2015.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TS has received research grants or lecture fees from Bayer, Boehringer Ingelheim, and Daiichi-Sankyo and Gottfried and Julia Bangerter Rhyner Foundation. MM has received research grants from the Gottfried and Julia Bangerter Rhyner Foundation. MN has received research grants or lecture fees from Bayer, CSL Behring, Roche diagnostics, and Instrumentation Laboratory. AKE is member of the advisory boards of all registered DOACs. JE reports no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"48"}}